A. Pastrak

发表

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

P. Tariot, D. Arnold, R. Sperling, 2011, Neurology.

Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2013, Clinical pharmacology in drug development.

Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2009, Alzheimer's & Dementia.

Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats

G. Koren, A. Nava-Ocampo, A. Pastrak, 2005, Clinical and experimental pharmacology & physiology.

Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study

T. Yorifuji, Y. Hasegawa, R. Rosenfeld, 2022, Hormone Research in Paediatrics.

Results From an Open-Label Extension of the Phase 2 Dose Finding Study of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency (GHD)

N. Mauras, V. Iotova, R. Rosenfeld, 2021, Journal of the Endocrine Society.

Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared to Daily Somatropin in Pediatric Patients With Growth Hormone Deficiency (pGHD)

M. Phillip, C. Deal, C. Roland, 2021 .

Phase 3 Study Evaluating Once Weekly Somatrogon Compared to Daily Genotropin in Japanese Patients With Pediatric Growth Hormone Deficiency (pGHD)

Toshiaki Tanaka, T. Yorifuji, Y. Hasegawa, 2021, Journal of the Endocrine Society.

Long-Term Safety of a Once-Weekly Somatrogon (hGH-CTP): 4-Year Results of a Phase 2 Extension Study in Children with Growth Hormone Deficiency

V. Iotova, R. Rosenfeld, Z. Zadik, 2019 .

An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment

N. Mauras, V. Iotova, Z. Zadik, 2023, Journal of pediatric endocrinology & metabolism : JPEM.

OR10-06 Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial

C. Deal, J. Cara, S. Valluri, 2020, Journal of the Endocrine Society.

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study

M. Phillip, C. Deal, C. Roland, 2022, The Journal of clinical endocrinology and metabolism.

PDB4 Evaluation of Quality of Life in PRE-Pubertal Children Using the Quality of Life in Short Stature Youth (QOLISSY) Questionnaire, Following 12 Months of Growth Hormone Treatment with Either a Weekly Somatrogon or a Daily Genotropin Injection Schedule

J. Quitmann, S. Valluri, C. L. Roland, 2020 .

Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues

Ying Ding, R. Belin, K. Bokvist, 2019, Diabetes, obesity & metabolism.

Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2013, Clinical pharmacology in drug development.